Fig 1.
Study site in Northern Ghana; administrative shapefiles obtained from National Information Technology Agency (NITA), Government of Ghana (https://data.gov.gh/dataset/shapefiles-all-districts-ghana-170-districts).
The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the authors, or the institutions with which they are affiliated, concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries.
Table 1.
Estimates of seroprevalence by antigen and disease, including distributions of responses for all individuals and individuals classified as exposed.
Table 2.
Mean posterior estimates of coefficients of fixed effects and spatial range, including 95% Bayesian credible intervals (BCI).
Fig 2.
Posterior estimates of the probability of exceeding 10% seroprevalence of high responders to A) Trachoma Pgp3; B) Lymphatic filariasis Wb123; C) Onchoceriasis Ov16; D) Strongyloidiasis NIE; E) Schistosomiasis SEA; F) Giardiasis VSP3; administrative shapefiles obtained from National Information Technology Agency (NITA), Government of Ghana (https://data.gov.gh/dataset/shapefiles-all-districts-ghana-170-districts).
Fig 3.
Combining disease measures to A) identify regions with high probabilities of exceeding 10% seroprevalence (exceedance probabilities > 70%); and B) identify regions with high uncertainty (exceedance probabilities 40–60%); administrative shapefiles obtained from National Information Technology Agency (NITA), Government of Ghana (https://data.gov.gh/dataset/shapefiles-all-districts-ghana-170-districts).
Fig 4.
Arithmetic mean MFI values per cluster by region.